Tags

Type your tag names separated by a space and hit enter

Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial.
World J Gastroenterol 2013; 19(25):4001-6WJ

Abstract

AIM

To measure a broad profile of pro- and anti-inflammatory cytokines in patients with clinically proven chronic pancreatitis (CP) taking either antioxidant therapy or placebo as part of the larger ANTICIPATE study.

METHODS

Patients with chronic pancreatitis were recruited to the ANTICIPATE study following informed consent and were randomised to intervention with either antox version 1.2-based antioxidant therapy or placebo. After a separate ethics committee amendment a subgroup of 7 patients from either arm of the study were selected for additional analysis of cytokines. Cytokines were measured at baseline and after 6 mo of either antox therapy or placebo by biochip array and enzyme-linked immunosorbent assay.

RESULTS

Antioxidant therapy and placebo groups were well-matched in terms of age, gender, aetiology of CP, opiate use and disease duration. Baseline antioxidant levels were similar in patients allocated to the antioxidant group as compared to the group allocated to placebo. After 6 mo of antioxidant therapy there was significant elevation in vitamin C levels in the intervention group: 17.6 μg/mL (12.8-29.3 μg/mL) compared to 4.8 μg/mL (1.6-9.1 μg/mL) in placebo (P < 0.001; 95%CI: 9.0-20.2) with similar trends in selenium levels. There was no elevation in a broad array of pro- and anti-inflammatory cytokines in the antioxidant group compared to placebo [interleukin (IL)-1B, IL-4, IL-6, IL-10, tumor necrosis factor-α] either at baseline or after 6 mo of antioxidant therapy.

CONCLUSION

Cytokine levels were low at baseline and at 6 mo despite a significant elevation in plasma antioxidants. In patients with CP, with opiate-dependent abdominal pain, circulating cytokine levels are low suggesting that pain in this disease is not simply a manifestation of inflammation.

Authors+Show Affiliations

Hepato-Pancreato-Biliary Surgery Unit, Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom.No affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23840145

Citation

Shah, Nehal, and Ajith K. Siriwardena. "Cytokine Profiles in Patients Receiving Antioxidant Therapy Within the ANTICIPATE Trial." World Journal of Gastroenterology, vol. 19, no. 25, 2013, pp. 4001-6.
Shah N, Siriwardena AK. Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. World J Gastroenterol. 2013;19(25):4001-6.
Shah, N., & Siriwardena, A. K. (2013). Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. World Journal of Gastroenterology, 19(25), pp. 4001-6. doi:10.3748/wjg.v19.i25.4001.
Shah N, Siriwardena AK. Cytokine Profiles in Patients Receiving Antioxidant Therapy Within the ANTICIPATE Trial. World J Gastroenterol. 2013 Jul 7;19(25):4001-6. PubMed PMID: 23840145.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. AU - Shah,Nehal, AU - Siriwardena,Ajith K, PY - 2013/02/16/received PY - 2013/03/27/revised PY - 2013/04/10/accepted PY - 2013/7/11/entrez PY - 2013/7/11/pubmed PY - 2014/2/18/medline KW - Antioxidant therapy KW - Chronic pancreatitis KW - Cytokine SP - 4001 EP - 6 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 19 IS - 25 N2 - AIM: To measure a broad profile of pro- and anti-inflammatory cytokines in patients with clinically proven chronic pancreatitis (CP) taking either antioxidant therapy or placebo as part of the larger ANTICIPATE study. METHODS: Patients with chronic pancreatitis were recruited to the ANTICIPATE study following informed consent and were randomised to intervention with either antox version 1.2-based antioxidant therapy or placebo. After a separate ethics committee amendment a subgroup of 7 patients from either arm of the study were selected for additional analysis of cytokines. Cytokines were measured at baseline and after 6 mo of either antox therapy or placebo by biochip array and enzyme-linked immunosorbent assay. RESULTS: Antioxidant therapy and placebo groups were well-matched in terms of age, gender, aetiology of CP, opiate use and disease duration. Baseline antioxidant levels were similar in patients allocated to the antioxidant group as compared to the group allocated to placebo. After 6 mo of antioxidant therapy there was significant elevation in vitamin C levels in the intervention group: 17.6 μg/mL (12.8-29.3 μg/mL) compared to 4.8 μg/mL (1.6-9.1 μg/mL) in placebo (P < 0.001; 95%CI: 9.0-20.2) with similar trends in selenium levels. There was no elevation in a broad array of pro- and anti-inflammatory cytokines in the antioxidant group compared to placebo [interleukin (IL)-1B, IL-4, IL-6, IL-10, tumor necrosis factor-α] either at baseline or after 6 mo of antioxidant therapy. CONCLUSION: Cytokine levels were low at baseline and at 6 mo despite a significant elevation in plasma antioxidants. In patients with CP, with opiate-dependent abdominal pain, circulating cytokine levels are low suggesting that pain in this disease is not simply a manifestation of inflammation. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/23840145/Cytokine_profiles_in_patients_receiving_antioxidant_therapy_within_the_ANTICIPATE_trial_ L2 - http://www.wjgnet.com/1007-9327/full/v19/i25/4001.htm DB - PRIME DP - Unbound Medicine ER -